Free Trial
→ $5,000 DOGE check? (From Altimetry) (Ad)

enGene Q4 2024 Earnings Report

enGene logo
$6.24 +0.12 (+2.01%)
As of 02/21/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Earnings HistoryForecast

enGene EPS Results

Actual EPS
-$0.34
Consensus EPS
-$0.40
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

enGene Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

enGene Announcement Details

Quarter
Q4 2024
Date
12/19/2024
Time
After Market Closes

Conference Call Resources

enGene Earnings Headlines

Piper Sandler Initiates Coverage on enGene (NASDAQ:ENGN)
February 20 at 2:31 AM | americanbankingnews.com
enGene (NASDAQ:ENGN) Cut to "Neutral" at UBS Group
February 17, 2025 | americanbankingnews.com
$5,000 DOGE check?
Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a portion of the savings DOGE makes in Federal cuts could be funneled back to taxpayers. The media was quick to dub it a DOGE Dividend, with claims circulating that we could all receive a $5,000 check in the mail.
February 22, 2025 | Altimetry (Ad)
Ducati opts for 2024 engine for all six MotoGP bikes
February 13, 2025 | msn.com
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 31, 2025 | businesswire.com
enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)
January 30, 2025 | businesswire.com
See More enGene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like enGene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on enGene and other key companies, straight to your email.

About enGene

enGene (NASDAQ:ENGN), through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

View enGene Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles